The present technology regards the utilization of CEACAM1 as a biomarker for cancer. In particular the present invention regards the detection and measurement of soluble CEACAM1 levels for the detection and diagnosis of melanoma.

Provided is a kit for detecting a glycoprotein contained in a sample using an optical condensation system, the kit comprising microparticles modified by host molecules and a dilution solution for diluting the sample, in which each of the host molecules binds specifically to the glycoprotein, the dilution solution comprises a blocking agent and a buffering agent, the pH value of the dilution solution is higher than the isoelectric point of the glycoprotein, the concentration of the blocking agent is lower than a concentration at which the non-specific adsorption between the host molecules is inhibited in an environment where a light-induced force does not act on the host molecules, and the salt concentration in the dilution solution is a concentration at which the microparticles modified by the host molecules cannot be precipitated by salting out.

The present disclosure is directed towards methods for evaluating the presence of a cancer within a subject. Such methods include obtaining a biological sample from the subject, identifying a biological component in the biological sample, wherein the identity of the biological component is indicative of the presence or absence of a cancer. The methods disclosed herein may further include quantifying the amount of the biological component in the biological sample, wherein the quantity of the biological component is indicative of the presence or absence of a cancer. The present disclosure is also directed to systems for evaluating the presence of cancer within a subject, such device including a biological component detector comprising nanowires functionalized with nanoparticles and antibodies.